|
SUMMARY
OF EXPERTISE
- Extensive
experience in new drug/biologic registration, regulatory
compliance and quality assurance.
- Strong
management and leadership abilities.
- Experienced
in establishing and developing regulatory affairs and quality
assurance systems.
- In-depth
knowledge of FDA regulations for GMP's, GCP's and GLP's.
EDUCATION:
| M.S. |
|
Quality Assurance & Regulatory Affairs, Temple
University, Graduate School of Pharmacy, Ambler, PA. |
|
M.B.A. |
|
Seton
Hall University, Graduate School of Business, South Orange,
NJ. |
|
B.S. |
|
Biology,
Brooklyn College, Brooklyn, NY. |
|
EXPERIENCE:
|
CURRENT
POSITION
(Dec. 2006 - present) |
|
Senior
Consultant Biologics Consulting Group Inc.
Belle Mead, NJ |
| |
|
|
| 2006 |
|
Vice
President, Worldwide Regulatory Affairs, Ethicon,
Inc.
Somerville, NJ
-
Led and directed worldwide regulatory affairs functions
for new product registrations (devices and device
combination products) and post-approval regulatory
activities.
- Responsible
for identifying and analyzing changes in worldwide
regulatory requirements and developing strategies
to address those changes relevant to the company's
products.
- Responsible
for regulatory review and approval of advertising/promotional
materials and labeling.
|
| |
|
|
| 2001
- 2005 |
|
Vice
President, Regulatory Policy & Quality Assurance,
Covance, Inc.,
Princeton, NJ
- Responsible
for all regulatory, quality assurance and compliance
activities associated with Phase II-IV clinical research.
- Directed
multifunctional regulatory projects for client companies
including preparing, and submitting clinical trial
and marketing approval applications and developing
strategies for drug approval.
- Launched
strategic regulatory consulting unit to assist small
pharmaceuticals and biotech companies in developing
and gaining approval of novel drugs and biologics.
- Developed
a regulatory policy unit to assess and address changes
to regulatory requirements for the development and
approval of drugs and biologics.
- Globalized
clinical quality assurance organization; harmonized
processes and procedures to address worldwide clinical
research requirements.
|
|
|
|
| 1999
- 2000 |
|
Vice
President, Regulatory Affairs & Quality Assurance,
ImClone Systems, Inc.
Somerville, NJ
- Developed
regulatory strategies and directed regulatory and
quality activities to gain FDA approval of therapeutic
monoclonal antibodies and vaccines.
- Expanded
and upgraded the quality assurance, validations and
regulatory affairs departments to support multiple
product development and pre-commercialization programs.
- Directed
the regulatory activities for several important FDA
meetings clearing the path for successful BLA filings.
- Established
the framework for FDA to grant Fast Track Designation
for the company's lead product. Secured Orphan Drug
Designation for the same product.
|
|
|
|
| 1996
- 1999 |
|
Vice
President, Regulatory Affairs & Quality Assurance,
Cytogen Corp.
Princeton, NJ
- Developed
and directed regulatory and quality assurance activities
to secure approval of prescription drugs and biologics
(Phases I-IV).
- Established
advertising /labeling policies and quality assurance
systems.
- Developed
a corporate quality policy for regulatory, clinical
and manufacturing activities
- Developed
quality systems and procedures for the manufacture
of multiple biologic products.
|
|
|
|
| 1993
- 1996 |
|
Senior
Director, Regulatory Affairs, Pharmacia, Inc.
Columbus, OH
- Developed
and implemented regulatory strategies for the approval
of prescription drug products within the U.S.
- Successfully
coordinated NDA submission activities of drug products
for cancer, urology, rheumatoid arthritis, ulcerative
colitis and smoking cessation.
- Centralized
the regulatory affairs organization enabling the standardization
of practices and procedures resulting in higher quality
NDA submissions and faster drug approvals.
- Key
regulatory affairs representative in merger transition
team between Pharmacia and Upjohn
|
|
|
|
| 1981
- 1993 |
|
Executive
Director, Regulatory Affairs, Pharmacia Laboratories
(Kabi Pharmacia, Inc.), Piscataway, NJ
- Directed
US regulatory activities including new drug registration
and compliance with FDA regulations and guidelines.
- Directed
and coordinated the successful filing of several NDAs
and NDA supplements.
- Spearheaded
the company's US taskforce for expediting the global
approval of new drugs.
- Led
FDA negotiations and directed the regulatory activities
to address compliance issues facing the company.
- Developed
and implemented a reorganization plan to centralize
the regulatory affairs department.
- Liaison
to FDA during plant inspections. Conducted internal
GMP, GLP and GCP audits
|
|
|
|
| 1977
- 1981 |
|
U.S.
Food and Drug Administration, East Orange, NJ
- Performed
establishment inspections of drugs, medical devices
and in-vitro diagnostics.
- Experienced
with FDA regulations including GMP's, GCP's and GLP's.
- Received
four letters of commendation for superior performance.
|
|
CERTIFICATIONS
AND RELATED ACTIVITIES
- Regulatory
Affairs Certified (RAC)
- Chair,
Ethics & Clinical Practice Committee, Association
of Clinical Research Organizations
- Chair,
Ethics Committee, Regulatory Affairs Professional
Society
- Editorial
Board, FOCUS, Regulatory Affairs Professional Society
- Instructor,
Regulatory and Legal Issues in Drug Development, Mercer
County Community College
|
Page
Updated
January 3, 2007
|